When Should Researchers Stop a Study Because Participants May Be Harmed?

When Does Participant Harm Mean the Research Should No Longer Continue?

A serious adverse event occurs. A safety signal becomes a pattern. Additional monitoring fails to control a newly recognized risk. Participants are being harmed more often or more severely than expected. Perhaps the study was paused while researchers investigated, but the resulting evidence does not restore confidence that continued exposure is justified.

At some point, modifying the protocol or waiting for more information may no longer be enough.

The difficult question is not whether research must stop whenever anyone is harmed. Some ethically permissible studies involve known risks, and an adverse event can occur even when those risks were properly assessed and managed. The relevant question is when continued exposure can no longer be ethically justified in light of what is now known.

Stop When the Remaining Risk Can No Longer Be Adequately Managed or Ethically Justified

How to Know When Continued Research Is No Longer Defensible

An Adverse Event Does Not Automatically Mean the Study Must Stop

Participants may experience adverse events during research for many reasons. Some events are expected consequences of a procedure. Others arise from participants' underlying conditions or unrelated causes. Even a serious event does not by itself establish that an entire study must permanently terminate.

OHRP distinguishes adverse events from unanticipated problems involving risks to participants or others. Under its framework, an unanticipated problem is generally unexpected in nature, severity, or frequency, related or possibly related to the research, and indicative of greater risk than previously known or recognized.

The response therefore depends on what the event tells researchers about the study's actual risk, not merely on the fact that something adverse occurred.

Stopping Becomes Relevant When the Risk-Benefit Balance Is No Longer Acceptable

The 2024 Declaration of Helsinki provides a direct ethical standard. Researchers may not engage in medical research involving human participants unless they are confident that risks and burdens have been adequately assessed and can be satisfactorily managed. When risks and burdens are found to outweigh potential benefits, researchers must assess whether to continue, modify, or immediately stop the research.

This means the decision is not triggered only by actual injuries. A sufficiently serious prospective danger can undermine the ethical justification before another participant is harmed.

The question builds on the broader assessment of whether new information has changed the original risk-benefit balance. Stopping becomes appropriate when the revised balance cannot be adequately repaired by reasonable safeguards or modification.

Stop When Serious Harm Is More Frequent Than Expected

A known complication may initially be considered acceptable because it is expected to be rare. If accumulating evidence shows that it occurs substantially more often, the original justification may no longer hold.

OHRP explicitly recognizes unexpected frequency as relevant when determining whether research presents greater risk than previously known. Its guidance also states that unexpected, related or possibly related, serious adverse events routinely warrant consideration of substantive changes to protect participants.

Researchers should therefore monitor patterns rather than treating each event as an isolated case.

Stop When Harm Is More Severe Than Expected

The frequency of an event can remain unchanged while its ethical significance increases because its consequences turn out to be more serious.

Suppose researchers anticipated a temporary adverse effect but accumulating evidence reveals a possibility of permanent impairment. The probability may be identical to the original estimate, yet the magnitude of harm has changed substantially.

This is why ongoing safety assessment should continue to distinguish probability from magnitude rather than relying on a single label such as “low risk.”

One Event Can Sometimes Be Enough

Researchers do not always need to wait for a statistical pattern.

A single catastrophic event that is plausibly related to the research may reveal a danger serious enough to require immediate interruption and reassessment. OHRP describes unexpected serious adverse events related or possibly related to research as the most important subset of adverse events representing unanticipated problems because they indicate greater risk than previously recognized.

Whether that single event ultimately requires permanent termination depends on causality, severity, available safeguards, participant benefit, alternatives, and the governing ethical framework. But waiting for several repetitions of a potentially catastrophic event merely to strengthen the dataset can itself become ethically indefensible.

Stop When Reasonable Safeguards Cannot Make the Risk Manageable

A new risk does not always require termination. Researchers may be able to reduce it through revised eligibility criteria, additional monitoring, procedural changes, lower exposure, improved emergency response, or other safeguards.

OHRP identifies measures such as modified inclusion or exclusion criteria, additional monitoring, suspension of enrollment, suspension of procedures, protocol modification, and revised consent information as possible responses to newly recognized risk.

Stopping becomes more compelling when those measures cannot reduce the residual risk to a level that remains ethically acceptable.

A Pause and a Stop Answer Different Questions

A temporary study pause is useful when an important uncertainty needs to be resolved before additional exposure can be justified. Stopping reflects a stronger conclusion: available evidence no longer supports resuming the affected research, or the conditions required for ethical continuation cannot reasonably be achieved.

A pause can end in resumption. A stop reflects the conclusion that the relevant activity should not resume in its current form.

You May Need to Stop Only Part of the Study

“Stop the study” can be too blunt a description of the available options.

A particular intervention may become unsafe while observational follow-up remains valuable and low risk. An optional research biopsy may become unjustifiable while the main trial remains acceptable. One dose level or participant subgroup may face an unacceptable risk that does not apply to others.

The ethical response should therefore match the source of harm. Protect participants from the unacceptable exposure without unnecessarily abandoning ethically justified activities.

Stopping New Enrollment Is Not the Same as Stopping Current Participants

Researchers may conclude that no additional participants should enter the study while facing a more complicated question about people already enrolled.

For someone currently receiving a research intervention, abrupt discontinuation could create withdrawal effects, loss of potential benefit, interruption of necessary monitoring, or other harm. OHRP's 2025 guidance on IRB written procedures specifically recommends consideration of participants already enrolled when research is suspended or terminated, including orderly termination or transfer where applicable.

The safest response for future participants and current participants may therefore differ.

Participant Welfare Can Require Continued Follow-Up After the Intervention Stops

Researchers may need to continue collecting safety information after an intervention is discontinued, particularly when delayed adverse effects are possible.

Follow-up can also be necessary to manage existing complications, communicate clinically relevant findings, or transition participants to appropriate care.

These activities should be distinguished from continuing the risky experimental exposure. Ending the intervention may be necessary precisely while safety follow-up becomes more important.

Stop When the Potential Benefit No Longer Justifies the Risk

A study can become ethically unacceptable even if risk itself does not increase.

Suppose interim evidence shows that an experimental intervention offers substantially less benefit than expected while its risks remain unchanged. The ratio between what participants may gain and what they are asked to bear has deteriorated.

Similarly, a superior established treatment may become available, reducing the justification for continuing a riskier experimental approach.

The Declaration of Helsinki explicitly requires reconsideration not only when risks and burdens outweigh potential benefits but also when there is conclusive proof of definitive outcomes.

Stop When Continuing Can No Longer Produce Sufficiently Valuable Knowledge

Participant exposure also requires scientific justification.

If convincing evidence shows that the study cannot answer its question, that the relevant outcome has already been established conclusively, or that methodological problems have made the remaining research uninformative, continuing to expose participants may no longer be justified.

This is not necessarily a safety stopping rule in the narrow sense, but it matters ethically because risk without sufficient scientific value loses an important part of its justification.

Do Not Let Sunk Costs Become an Ethical Argument

A study may have consumed years of work, substantial funding, difficult recruitment, expensive infrastructure, and considerable professional effort. None of those facts makes participant harm more acceptable.

The relevant question is prospective: given what is known now, is continuing the exposure justified?

Researchers should be particularly alert to reasoning such as “we only need 20 more participants” or “we have already completed 90% of recruitment.” Nearness to the finish line does not alter the ethical status of the next participant's risk.

Stopping Rules Should Be Planned Before They Are Needed

Some studies, particularly interventional trials, can define safety, efficacy, or futility stopping criteria prospectively. These may be incorporated into the protocol and overseen by appropriate monitoring mechanisms.

Predefined criteria reduce the temptation to reinterpret concerning data after researchers have become invested in completing the study.

Not every type of research can use numerical stopping boundaries, however. Qualitative, behavioral, observational, and other studies may require more contextual criteria, such as unexpected severe distress, confidentiality failures, or evidence that particular procedures are causing greater harm than anticipated.

Stopping Rules Do Not Replace Judgment

A protocol may specify numerical safety thresholds, but unexpected harms can arise outside those criteria.

Conversely, crossing a statistical monitoring boundary may require expert review rather than an investigator independently treating the number as a complete ethical judgment.

Stopping criteria help structure decision-making. They do not eliminate the need to understand what the evidence means for participants.

Independent Oversight Matters Most When Researchers Have Reasons to Continue

Investigators naturally want their studies to succeed. Sponsors may have financial or strategic interests. Participants themselves may strongly wish to continue an intervention they believe is helping them.

Those motivations do not imply misconduct, but they make independent oversight valuable.

Under the U.S. Common Rule, an IRB has authority to suspend or terminate approval of research that is not being conducted in accordance with IRB requirements or that has been associated with unexpected serious harm to participants. A suspension or termination must include the reasons for the action and be promptly reported to specified parties.

Other regulatory systems assign relevant authority to research ethics committees, sponsors, institutions, data and safety monitoring bodies, regulators, or combinations of these. Researchers should know which body has decision-making authority for their particular study.

Stopping a Study Does Not End Ethical Responsibilities

Termination creates new obligations rather than erasing old ones.

Researchers may need to inform participants, explain what the decision means for them, arrange appropriate medical or other follow-up, preserve or transfer necessary care, report the termination, manage collected data and specimens appropriately, and communicate relevant new safety information.

OHRP's current guidance recommends that institutional procedures for suspension or termination address participants already enrolled, including informing them and planning orderly termination or transfer where appropriate.

Researchers also retain responsibilities concerning appropriate dissemination of findings. The Declaration of Helsinki states that negative and inconclusive results, as well as positive results, should be made publicly available.

Participants Should Not Learn About a Safety Stop by Accident

When termination affects current participants, communication should be timely and understandable.

Participants may need to know why the intervention or study has stopped, what is known and uncertain about the risk, whether they require additional monitoring, what happens to scheduled procedures, and what alternatives or follow-up arrangements are available.

The amount and urgency of information depend on the study and the participant's situation, but stopping for safety should not be treated merely as an internal administrative event.

When Additional Safeguards Are No Longer Enough

The stopping decision is not based simply on the number of adverse events. It follows from the combined evidence that the harm is more consequential than originally understood, expected benefit has weakened, and reasonable safeguards cannot restore an acceptable ethical balance.

Common Mistakes When Deciding Whether to Stop Research

Stop the Exposure That You Can No Longer Defend

Do not frame the decision as an emotional choice between “giving up” and “finishing the research.” Reconstruct the ethical justification using the evidence available now.

The threshold is not “has anyone been harmed?” It is whether, given what is now known and what can reasonably be done about it, continuing to expose participants remains ethically defensible.

Before Deciding Whether Research Should Stop, Check These

Frequently Asked Questions About Stopping Research for Participant Harm

Research Should Stop When Continued Exposure Can No Longer Be Defended

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.